Free Trial
ASX:CU6

Clarity Pharmaceuticals (CU6) Stock Price, News & Analysis

Clarity Pharmaceuticals logo

About Clarity Pharmaceuticals Stock (ASX:CU6)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
$1.17 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.

Receive CU6 Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Clarity Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CU6 Stock News Headlines

White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon bring Elon Musk's DOGE operation to its final, dramatic conclusion - with huge consequences for millions of investors. So if you have any money in the market... you're almost out of time to prepare. This plan has already been put in place... and can operate even if Elon's long gone from Washington.
See More Headlines

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Biotechnology
Sub-Industry
Pharmaceutical Products
Current Symbol
ASX:CU6
CIK
N/A
Fax
N/A
Employees
41
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$42.32 million
Net Margins
-481.09%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$11.51 million
Price / Cash Flow
N/A
Book Value
A$0.51 per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$1.17 billion
Optionable
Not Optionable
Beta
1.58
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (ASX:CU6) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners